• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Displaying 9-23 of 311 results

8 Institution Decision: Institution of Inter Partes Review35 USC sec 314

Document IPR2019-00451, No. 8 Institution Decision - Institution of Inter Partes Review35 USC sec 314 (P.T.A.B. Aug. 13, 2019)
On this record, and upon review of Petitioner’s arguments and supporting evidence, we determine that Petitioner sufficiently explains why one of ordinary skill in the art would have looked to Meezan ’962’s disclosure when seeking to enhance the bioavailability of the therapeutic agents in the compositions disclosed in Gwozdz.
For the reasons stated supra with regard to claims 8–10 and 15, Petitioner’s assertion that Patent Owner never showed any unexpected results with respect to the amount of ethanol and benzyl alcohol is not sufficiently supported by the evidence of record.
We are not persuaded that Petitioner and Dr. Peppas have provided sufficient argument and supporting evidence to explain why one of ordinary skill in the art would have reasonably expected success in achieving the bioavailabilities recited in claims 34–36 of the ’876 patent when combining the teachings of Gwozdz and Meezan ’962.
Petitioner argues that, since neither Gwozdz nor Meezan ’962 provide specific dosing regimens for benzodiazepines/diazepam, one of ordinary skill in the art would look to the similar reference of Cartt ’784, titled “Nasal Administration of Benzodiazepines,” for these teachings.
On this record, and upon review of Petitioner’s arguments and supporting evidence, we determine that Petitioner sufficiently explains why one of ordinary skill in the art would have looked to Cartt ’784’s disclosure when seeking dosing regimens for the compositions disclosed in Gwozdz and Meezan ’962.
cite Cite Document

5 Notice of Filing Date Accorded to Petition: NOTICE OF FILING DATE ACCORDED TO PETITIONANDTIME FOR FILING PATENT OWNER PRELIMINARY RESPONSE

Document IPR2019-00451, No. 5 Notice of Filing Date Accorded to Petition - NOTICE OF FILING DATE ACCORDED TO PETITIONANDTIME FOR FILING PATENT OWNER PRELIMINARY RESPONSE (P.T....
Patent Owner may file a preliminary response to the petition no later than three months from the date of this notice.
Patent Owner may also file an election to waive the preliminary response to expedite the proceeding.
Patent Owner is advised of the requirement to submit mandatory notice information under 37 C.F.R. § 42.8(a)(2) within 21 days of service of the petition.
The parties are advised that under 37 C.F.R. § 42.10(c), recognition of counsel pro hac vice requires a showing of good cause.
Such motions shall be filed in accordance with the “Order -- Authorizing Motion for Pro Hac Vice Admission” in Case IPR2013-00639, Paper 7, a copy of which is available on the Board Web site under “Representative Orders, Decisions, and Notices.” The parties are reminded that unless otherwise permitted by 37 C.F.R. § 42.6(b)(2), all filings in this proceeding must be made electronically in the Patent Review Processing System (PRPS), accessible from the Board Web site at http://www.uspto.gov/PTAB.
cite Cite Document

42 Reply: Patent Owners Reply to Petitioner¿¿¿s Opposition to Patent Owner¿¿¿s Motion to Exclude Evidence

Document IPR2019-00451, No. 42 Reply - Patent Owners Reply to Petitioner¿¿¿s Opposition to Patent Owner¿¿¿s Motion to Exclude Evidence (P.T.A.B. May. 5, 2020)
Aquestive fails to show why EX1013—a document that is cited only in support of a non-instituted ground—(and Dr. Peppas’ discussion thereof, EX1041, ¶¶171-191, 264-362, Appendix A (pp. 197-224), and EX1050) is relevant to the instituted grounds.
Aquestive’s reliance on Genzyme Therapeutic and/or Ariosa Diagnostics is disingenuous given that neither of those decisions involved the lack of notice, and resultant prejudice, that is present here.
The declaration does not provide any “personal knowledge” as required by FRE 901(b)(1), or any other evidence that EX1069 is what Aquestive purports it to be—a manual available to, and followed by, medical technicians in Florida prior to the priority date.
Separately, Dr. Wermeling’s experience in drug development does not qualify him to provide expert opinions on economics and/or regulatory procedures.
Aquestive block cites portions of Dr. Wermeling’s testimony in support of the alleged “expertise”—but, a closer look at the testimony reveals that he (1) is merely “familiar with economic principles” (EX2031, 8:19-22) and otherwise collaborated with trained economists for his written work (id., 10:2-14); (2) has never worked at, or received any formal certifications related to, FDA practice and procedure (id., 10:22-11:7); (3) has limited experience with pricing (id., 77:2-7) and could not make any pricing decisions on his own (id., 79:24-80:81:5), and; (4) is only “pretty familiar” with the 505(b)(2) pathway and would need to consult the “regulatory person at the company” for the answer to a complex question on the same (id., 85:6-86:13).
cite Cite Document

41 Reply: PETITIONERS REPLY IN SUPPORT OF ITS MOTION TO EXCLUDE EVID...

Document IPR2019-00451, No. 41 Reply - PETITIONERS REPLY IN SUPPORT OF ITS MOTION TO EXCLUDE EVIDENCE (P.T.A.B. May. 5, 2020)

cite Cite Document

39 Opposition: Patent Owners Opposition to Petitioners Motion to Exclude

Document IPR2019-00451, No. 39 Opposition - Patent Owners Opposition to Petitioners Motion to Exclude (P.T.A.B. Apr. 28, 2020)

cite Cite Document

38 Opposition: PETITIONERS OPPOSITION TO PATENT OWNERS MOTION TO E...

Document IPR2019-00451, No. 38 Opposition - PETITIONERS OPPOSITION TO PATENT OWNERS MOTION TO EXCLUDE EVIDENCE (P.T.A.B. Apr. 28, 2020)

cite Cite Document

35 Motion: Patent Owner¿¿¿s Motion to Exclude Evidence 37 CFR ¿¿4264

Document IPR2019-00451, No. 35 Motion - Patent Owner¿¿¿s Motion to Exclude Evidence 37 CFR ¿¿4264 (P.T.A.B. Apr. 21, 2020)

cite Cite Document

34 Motion: PETITIONERS MOTION TO EXCLUDE PURSUANT TO 37 CFR ¿¿ 4264c

Document IPR2019-00451, No. 34 Motion - PETITIONERS MOTION TO EXCLUDE PURSUANT TO 37 CFR ¿¿ 4264c (P.T.A.B. Apr. 21, 2020)

cite Cite Document

28 Reply: Patent Owners Surreply

Document IPR2019-00451, No. 28 Reply - Patent Owners Surreply (P.T.A.B. Mar. 10, 2020)

cite Cite Document

26 Other Not for motions: PARTIES JOINT SUBMISSION OF PATENT OWNERS ID...

Document IPR2019-00451, No. 26 Other Not for motions - PARTIES JOINT SUBMISSION OF PATENT OWNERS IDENTIFICATION OF NEW ARGUMENTS AND PETITIONERS RESPONSES THERETO (P.T...

cite Cite Document

45 Notice of Appeal: Patent Owner Neurelis, Incs Notice of Appeal

Document IPR2019-00451, No. 45 Notice of Appeal - Patent Owner Neurelis, Incs Notice of Appeal (P.T.A.B. Oct. 8, 2020)

cite Cite Document

21 Reply: PETITIONERS REPLY TO PATENT OWNERS RESPONSE TO THE PETI...

Document IPR2019-00451, No. 21 Reply - PETITIONERS REPLY TO PATENT OWNERS RESPONSE TO THE PETITION (P.T.A.B. Jan. 28, 2020)

cite Cite Document

18 Other Not for motions: Petitioners First Updated Mandatory Notices Update

Document IPR2019-00451, No. 18 Other Not for motions - Petitioners First Updated Mandatory Notices Update (P.T.A.B. Nov. 15, 2019)

cite Cite Document

37 Exhibit List: PETITIONERS SECOND UPDATED EXHIBIT LIST

Document IPR2019-00451, No. 37 Exhibit List - PETITIONERS SECOND UPDATED EXHIBIT LIST (P.T.A.B. Apr. 28, 2020)

cite Cite Document

40 Exhibit List: Patent Owners Updated Exhibit List

Document IPR2019-00451, No. 40 Exhibit List - Patent Owners Updated Exhibit List (P.T.A.B. Apr. 28, 2020)

cite Cite Document
<< 1 2 3 4 5 ... >>